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MEDIUM-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY: A 
CHARCTERIZATION OF THE MOST COMMON VARIANT AND CURRENT 
AND FUTURE THERAPEUTICS 
 
GABRIELLE BARBERA 
 
ABSTRACT 	
Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) is the most common 
inborn error of metabolism affecting the fatty acid oxidation pathway. The deficiency is 
caused by a defect in the medium-chain acyl-CoA dehydrogenase enzyme which 
catalyzes the first step in the oxidation of medium-chain fatty acids. Long-chain fatty 
acids, after being transported into the mitochondria and activated into long-chain acyl-
CoAs, are sequentially broken down until they become medium-chain acyl-CoAs. 
Medium-chain acyl-CoAs are then broken down until they become short-chain acyl-
CoAs. Short-chain acyl-CoAs are broken down until only acetyl-CoA remains. The block 
in the oxidation of fatty acids in those with MCADD happens once the long-chain acyl-
CoAs have been oxidized to medium-chain acyl-CoAs. The medium-chain acyl-CoAs 
cannot be further oxidized and build up. Without the breakdown of fatty acids, 
individuals with MCADD cannot produce enough energy during times of increased 
metabolic demand. Thus, prolonged exercise, fasting, or fever can precipitate clinical 
symptoms once the body enters a hypoketotic hypoglycemic state. Those with MCADD 
typically present in the early months of life with fasting intolerance, vomiting, lethargy, 
		 v 
and, in more serious cases, seizures. Adult presentation is rare, but should not be ruled 
out of a differential diagnosis, because early detection and intervention can prevent 
permanent brain damage and death. 
Because early detection can prevent the serious effects of metabolic 
decompensation, MCADD was added to the Newborn Screen and is tested through 
measuring levels of medium-chain acylcarnitines in dried blood smears by tandem mass 
spectrometry. Metabolic decompensation is manifested clinically through dehydration, 
vomiting, and acidosis. In serious cases, metabolic decompensation can progress to 
seizures, coma, and death. Introduction of the Newborn Screen has reduced the morbidity 
of the deficiency, but has not eliminated it. Those with MCADD need to be closely 
monitored and emergency glucose needs to be available to them in case of a 
hypoglycemic emergency. The Newborn Screen has been effective in finding mutations 
in the ACADM gene that produce a mild phenotype of MCADD. Before the Newborn 
Screen, the most common variant, K329E, was detected in clinically diagnosed patients. 
However, the screen has shown that there are about 150 variants leading to MCADD. 
The most common variant of the MCAD protein, K329E, has been studied and 
characterized in order to further understand the pathogenesis of MCADD. This mutation 
substitutes a lysine for a glutamic acid, introducing hindrance and the inability of the 
protein to form its fully functional tetrameric form. The mutant protein also has an 
increased sensitivity to heat denaturation. Currently, there are no pharmacological 
treatments for MCADD. The idea of pharmacological chaperones is explored by using 
the example of tetrahydrobiopterin and phenylketonuria. Future studies will need be done 
		 vi 
to find a treatment for MCADD that is curative rather than treating the symptoms of the 
deficiency; however, curative therapies which target the mutant enzyme may be 
problematic since there is a wide array of mutations that result in a defective enzyme in 
affected individuals. 
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INTRODUCTION 
 
In the first part of this thesis, a characterization of the most common variant of the 
ACADM gene leading to Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency 
(MCADD) will be described. This characterization will include an assessment of the 
enzyme’s catalytic pockets, catalytic activity, thermal and proteolytic stability, and 
motion patterns in the presence of substrates. The second part will include a summary of 
the current therapies used to treat those with MCADD. The final part of this thesis will 
speculate on future therapeutics that could be developed to treat those with MCADD by 
examining pharmacological chaperones approved for the treatment of other inborn errors 
of metabolism caused by a defective enzyme. The following introduction will give a brief 
history of MCADD, an overview of the mitochondrial fatty acid oxidation pathway, the 
pathophysiology and clinical presentation of MCADD, advancements in the newborn 
screen (NBS) and the genetics of MCADD.		
Brief History 
MCADD is the most common inborn error of metabolism that affects the mitochondrial 
fatty acid oxidation pathway (Bonito et al., 2016). MCADD results from a deficiency in 
the medium-chain acyl-CoA dehydrogenase enzyme which catalyzes the first step in the 
mitochondrial β-oxidation of medium-chain fatty acids (Grosse et al., 2006) (Figure 1). 
The incidence of MCADD in populations of European descent is reported to be from 1 in 
10,000 to 1 in 27,000 births, and it is shown to be less common in those of non-European 
	2 
 
 
 
Figure 1: The Four Steps of the Fatty Acid β-oxidation Cycle. First, long-chain fatty 
acids, after being transported into the mitochondria and activated into long-chain acyl-
CoAs, are oxidized to medium-chain acyl-CoAs. Medium-chain acyl-CoAs then get 
oxidized to short-chain acyl-CoAs. Short-chain acyl-CoAs get oxidized until only acetyl-
CoA is left. The acyl-CoA dehydrogenases, each having an affinity for either long-chain, 
medium-chain, or short-chain fatty acids, use FAD as an electron acceptor. FADH2 needs 
to be re-oxidized, which is done by the electron transfer flavoprotein (a heterodimer of 
ETFα and ETFβ).  ETF dehydrogenase (ETFDH) transfers the electrons to coenzyme Q 
(Q) which feeds into oxidative phosphorylation (OXPHOS) and leads to the production 
of ATP. NADH is also produced and feeds into OXPHOS. Acetyl-CoA feeds into the 
citric acid cycle or can be used for ketogenesis. The acyl-CoA goes through β-oxidation 
again. Adapted from (Houten et al., 2016) 
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origin (Grosse et al., 2006). MCADD was first characterized in 1982 and studied in 
patients with C6-C10 dicarboxylic aciduria presenting with Reye’s like syndrome (Kølvraa 
et al., 1982). It had a mortality rate of 16-25% for those diagnosed clinically before it was 
added to the NBS (Wilcken, 2010). 
In the 1990s, MCADD was added to the list of diseases and deficiencies screened 
in the NBS done by tandem mass spectrometry of blood splots (Rhead, 2006). MCADD 
was added to the NBS not only because of its high mortality rate in infants, but also 
because the mortality and severe side effects of MCADD like encephalopathy, 
intellectual disabilities, and Reye’s like syndrome can be prevented if the presence of the 
deficiency is known.  The NBS has resulted in the diagnosis of patients with MCADD 
who show no clinical characteristics of the deficiency. This has expanded the number of 
known mutations leading to MCADD and the discovery of certain variants that will show 
either no or very mild symptomology (Grosse et al., 2006). MCADD is a genetically 
heterogeneous disease with about 150 identified mutations in the ACADM gene known to 
lead to a deficient medium-chain acyl-CoA dehydrogenase enzyme (Smith et al., 2010).  
MCADD is diagnosed based on the detection of biomarkers in the blood and urinary 
medium-chain dicarboxylic acids (Bastin, 2014). Currently, MCADD is best treated with 
an avoidance of fasting. Some patients are treated with L-carnitine supplementation, but 
there is debate over its efficacy (Walter, 2003). There is no cure for MCADD and there is 
no pharmacological intervention to date for the treatment of MCADD. 
 
	4 
Mitochondrial Fatty Acid β-Oxidation 
The three main substances used for an organism to generate energy are glucose, amino 
acids, and fatty acids (Houten and Wanders, 2010). Glucose is utilized first through 
glycolysis and then through other pathways, such as the citric acid cycle and later, 
oxidative phosphorylation for energy production (Fromm and Hargrove, 2012a). Amino 
acid breakdown products, mostly acetyl-CoA, are used in energy production (Fromm and 
Hargrove, 2012b). Fatty acids are broken down mainly through fatty acid β-oxidation in 
the mitochondria. Fatty acid metabolism is critical when glucose supplies in the organism 
are low, such as during times of fasting or when glucose supplies are being rapidly used 
as during periods of increased metabolic demand on the body, such as during extreme 
exercise or fever (Houten and Wanders, 2010). Tissues such as the liver, skeletal muscle, 
and the heart can use fatty acid metabolism for energy during times when glucose 
supplies are low. Fatty acid breakdown in the liver is used to produce not only energy, 
but also ketone bodies. During periods of fasting, fever, or severe exercise, these ketones 
are used for energy by the heart, muscle, and other tissues and can be seen as a “glucose 
sparing mechanism” which provides an alternate fuel, ketone bodies, for some tissues, 
while saving glucose for the brain (Olpin, 2013). The brain uses glucose exclusively 
except during severe fasting when it can use ketone bodies for energy, at which time 
other tissues like muscle will switch back to fatty acid metabolism for energy sparing 
ketones for the brain (Houten and Wanders, 2010). The mitochondrial fatty acid β-
oxidation pathway has been extensively studied and well characterized. It plays a critical 
role in energy homeostasis. 
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In order to be broken down, the fatty acids must be transported into the 
mitochondrial matrix. The carnitine shuttle is used to regulate the import of long-chain 
fatty acids into the mitochondria where β-oxidation occurs (Houten et al., 2016). The 
long-chain fatty acid is first activated in the cytosol by acyl-CoA synthetase. The fatty 
acyl-CoA is converted into acylcarnitine by carnitine palmitoyltranferase I (CPTI) and 
transported across the membrane by carnitine acylcarnitine translocase (Houten and 
Wanders, 2010) (Figure 2). Once inside the mitochondria, the fatty acylcarnitine is 
converted back into fatty acyl-CoA by carnitine palmitoyl transferase II and is degraded 
into acetyl-CoA units (Houten and Wanders, 2010).  Long-chain acyl-CoAs are degraded 
cyclically into medium-chain and short-chain acyl-CoAs until acetyl-CoA is left. This is 
done by a unique set of enzymes that have affinity first for the long-chain acyl-CoAs, 
then the medium-chain acyl-CoAs, and finally, the short-chain acyl-CoAs. Those with 
MCADD have a deficiency in the oxidation of the medium-chain acyl-CoAs. Thus, the 
block in β-oxidation occurs once long-chain acyl-CoAs are oxidized into medium-chain 
acyl-CoAs. The medium-chain acyl-CoAs cannot be oxidized further and build up. Steps 
for the oxidation of acyl-CoAs are shown in Figure 1. First, an acyl-CoA dehydrogenase 
catalyzes the dehydrogenation of the acyl-CoA into a trans-2-enoyl-CoA (Houten et al., 
2016). This step is defective for medium chain acyl-CoAs in those with MCADD. 
Second, enoyl-CoA hydratase catalyzes the hydration of trans-2-enoyl-CoA into (S)-3-
hydroxyacyl-CoA (Houten et al., 2016). Next, (S)-3-hydroxyacyl-CoA undergoes a 
dehydrogenation reaction catalyzed by (S)-3-hydroxyacyl-CoA dehydrogenase to form 3-
ketoacyl-CoA (Houten et al., 2016). The fourth step requires cleavage by a thiolase to  
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Figure 2: Carnitine Shuttle. Adapted from (Wikimedia Commons Contributors, 2014).  
 
 
 
 
	7 
produce a two-carbon shorter acyl-CoA and an acetyl-CoA (Houten et al., 2016). This 
process repeats until the fatty acyl-CoA is completely broken down into acetyl-CoAs 
(Fromm and Hargrove, 2012c). The products of this cyclic degradation go on to be used 
in the synthesis of ATP. 
Each cycle of β-oxidation results in one acetyl-CoA, one NADH and one FADH2. 
Acetyl-CoA feeds into the citric acid cycle. The citric acid cycle, through a series of 
enzymatic reactions, converts acetyl-CoA into CO2 and energy (Fromm and Hargrove, 
2012d). The citric acid cycle produces most of the energy by creating reduced coenzyme 
intermediates like FADH2 and NADH (Fromm and Hargrove, 2012d). Together with the 
NADH and FADH2 produced from acetyl-CoA in the citric acid cycle, the NADH and 
FADH2 from fatty acid β-oxidation are used in oxidative phosphorylation to produce 
ATP and oxidized coenzymes that can be recycled and re-used in another cycle of the 
citric acid cycle or β-oxidation (Fromm and Hargrove, 2012e). An understanding of the 
underlying biochemical and molecular pathways involved in fatty acid break down and 
its use in energy production is key to understanding the pathophysiology of MCADD. 
 
Pathophysiology Overview 
The pathophysiology of MCADD results from the failure of fatty acid breakdown to 
produce energy especially during times of increased need like during prolonged exercise 
or febrile illness (Bennett, 2010). The main organ impacted is the liver and most of the 
pathophysiology can be explained through the liver dysfunction, as can be seen in Figure 
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3. In a large retrospective French multicenter study which analyzed 187 children 
suffering from disorders of fatty acid metabolism, it was found that 89% of patients 
presented with hepatic symptoms irrespective of the underlying metabolic deficiency 
(Baruteau et al., 2013). In particular, the study found that 92% of patients had an enlarged 
liver, 82% had elevated blood alanine aminotransferase levels, which is a sign of liver 
dysfunction, and 88% had steatosis of the liver (Baruteau et al., 2013). These findings 
support the fact that the liver is the critical organ involved in the integration of 
gluconeogenic and β-oxidation pathways which work together to provide fuel during 
times of prolonged fasting, fever, or severe exercise. The deficiency’s effect on the body 
can be characterized in three ways: inadequate cellular energy, lack of ketones as an 
alternative fuel and the accumulation of a toxic metabolite (Walter, 2009). It is the lack of 
fuel and the production of a toxic metabolite which leads to the severe metabolic 
decomposition seen in those with MCADD. 
 
Pathophysiology: Inadequate fuel sources 
Inadequate cellular energy is manifested through hypoglycemia and low plasma ketones 
resulting from liver dysfunction. In those with MCADD, mitochondria contain the 
defective medium-chain acyl-CoA dehydrogenase enzyme; thus, fatty acids cannot be 
used as fuel or converted into ketones to be used as fuel. Products of fatty acid 
metabolism are also not around in high enough amounts to stimulate gluconeogenesis. 
Inadequate energy leads to liver, skeletal muscle, cardiac and brain abnormalities (Figure 
	9 
3). Reduced levels of body fuels make those with MCADD susceptible to severe 
metabolic decompensation where the body is in a critical catabolic state trying to provide 
energy for vital functions. This catabolic state, if not recognized and treated, can result in 
lasting neurological damage or death. 
 
 
Figure 3: Overview of the Pathophysiology Present in MCADD. Liver dysfunction 
leading to low plasma ketones, hypoglycemia and hyperammonemia results in 
neurological abnormalities. Heart dysfunction results in arrhythmias and 
cardiomyopathies. Not shown in the figure are skeletal muscle abnormalities due to the 
hypoglycemia that lead to muscle weakness and, in severe cases, muscle breakdown. 
Adapted from (Bastin, 2014). 
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Hypoglycemia results primarily from the body’s inability to support 
gluconeogenic pathways during times of increased demand (Olpin, 2013). During times 
of increased need, glucose is produced from gluconeogenic pathways in the liver. This 
production requires acetyl-CoA, ATP, and NADH which are made during fatty acid β-
oxidation (Olpin, 2013). Fatty acid β-oxidation has been shown to stimulate 
gluconeogenesis both in vitro and in vivo because of the requirement of acetyl-CoA as an 
activator for the rate limiting step of gluconeogenesis catalyzed by pyruvate carboxylase 
(Fanelli et al., 1993; Williamson et al., 1966). Much, if not all, of the glucose produced is 
used by the brain while fatty acids or ketones are used by other organs, such as skeletal 
muscle and the heart for fuel during times of increased need. In those with MCADD, β-
oxidation is impaired, acetyl-CoA, ATP, and NADH are not produced in great amounts 
resulting in inadequate production of glucose (Olpin, 2013). Ketone production is also 
believed to be impaired in those with MCADD. 
 Ketone production is believed to be impaired because of the defect in the β-
oxidation of medium chain fatty acids (Olpin, 2013). Ketones, acetone and D-β-
hydroxybutyrate are produced from acetyl-CoA as shown in Figure 4. In the first step 
catalyzed by a thiolase, two acetyl-CoAs, produced from β-oxidation, come together to 
form acetoacetyl-CoA (Figure 4). β-hydroxy-β-methylglutaryl-CoA synthase (HMG-
CoA synthase) catalyzes the next step which produces HMG-CoA.  HMG-CoA then 
becomes acetoacetate via HMG-CoA lyase. Acetoacetate can then become either acetone 
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or D-β-hydroxybutyrate. Production of D-β-hydroxybutyrate is catalyzed by D-β-
hydroxybutyrate dehydrogenase and the production of acetone is spontaneous. 
 
 
Figure 4. Ketone Production. Adapted from (Wikimedia Commons Contributors, 2012) 
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In one study, it was found that a group of mildly fasting MCADD patients actually had 
the same ketone levels as controls (Fletcher and Pitt, 2001). This suggests that there is 
enough residual fatty acid oxidation from long and short chain fatty acids in those with 
MCADD who are not in a metabolic crisis (Fletcher and Pitt, 2001). Low plasma ketone 
levels do not become pronounced in those with MCADD until there is an increased need 
for energy (Fletcher and Pitt, 2001). Thus, during fasting, severe exercise, or fever, those 
with MCADD enter a hypoketotic hypoglycemic state which has effects on the liver, 
skeletal muscle, brain and heart.  
Liver dysfunction results from inadequate amounts of ATP and accumulation of 
fatty acids. The liver does not have enough energy to undergo normal metabolic 
processes because of the low availability of energy sources. One major effect is that the 
liver cannot function in ureagenesis (Bastin, 2014). The urea cycle is impaired leading to 
an accumulation of ammonia (Olpin, 2013).  Also, medium-chain fatty acids build up in 
the liver since they cannot be broken down by β-oxidation which leads to steatosis of the 
liver (Olpin, 2013). In a similar way, the brain is affected by low fuel stores. 
The brain uses glucose as its major energy source. During times of severe fasting, 
the brain can use ketone bodies as an alternate source of energy. In MCADD, there is 
both hypoglycemia and low plasma ketone levels leaving the brain with no alternative 
fuel (Feillet et al., 2003). The brain does not have enough fuel to function properly. The 
hyperammonemia which results from the liver being unable to perform the urea cycle can 
lead to coma (Feillet et al., 2003). The absence of ketone bodies can lead to a glutamine 
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build up in the brain and seizures (Feillet et al., 2003). Liver and brain pathophysiology is 
seen in almost all cases of MCADD. However, the effects on the heart and skeletal 
muscle have been debated. 
A milder skeletal muscle phenotype is observed in MCADD compared to other 
defects in fatty acid β-oxidation (Madsen et al., 2013). This may be due to the fact that 
during periods of prolonged fasting skeletal muscles primarily use long-chain fatty acids 
as fuel. However, in a prolonged catabolic state, skeletal muscle energy production can 
become impaired once medium-chain fatty acids are relied upon as fuel after all of the 
long-chain fatty acids have been broken down into medium-chain fatty acids (Bastin, 
2014). In one study comparing the effect of low intensity exercise in patients with 
MCADD versus controls, it was found that at rest oxidation rates were the same between 
the two groups (Madsen et al., 2013). This is probably due to sufficient oxidation of long 
chain fatty acids. However, during prolonged intense-to-moderate exercise, oxidation was 
found to increase in both MCADD patients and controls, but it increased further in 
controls (Madsen et al., 2013). This supports the suspicion that muscle oxidation 
becomes impaired in those with MCADD upon increased energy need as during 
prolonged intense exercise and may result in muscle weakness, muscle breakdown, and 
exercise intolerance (Olpin, 2013). Severe muscle breakdown and rhabdomyolysis may 
also occur in some patients due to the inhibition of sodium/potassium ATPases, calcium 
ATPases and the calcium sodium exchanger in muscles due to the depletion of ATP 
(Warren et al., 2002). The accumulation of fatty acid intermediates may also lead to 
eventual skeletal muscle damage (Houten et al., 2016). Cardiac effects have also been 
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debated since the heart, like skeletal muscle, primarily uses long-chain fatty acids as fuel 
during periods of prolonged fasting (Bastin, 2014). 
There have been some reports on cardiac abnormalities seen in those with 
MCADD. In 2003, a case report of an adult with MCADD reported that the patient had 
ventricular tachycardia and supraventricular tachycardia which eventually led to 
ventricular fibrillation and cardiac arrest (Feillet et al., 2003). In 2006, a retrospective 
study in the Netherlands reported no cardiac abnormalities in 11 adult patients studied 
with MCADD (Derks et al., 2006). In 2014, the first report was published of a child born 
with MCADD who had a prolonged QTc interval in electrocardiogram analysis (Wiles et 
al., 2014). No arrhythmia was detected in this patient, but the child’s QTc interval was 
517 milliseconds compared to 440 milliseconds for normal and was found to go back to 
normal after the metabolic disturbance was corrected (Wiles et al., 2014). Similar to 
skeletal muscle, the heart mostly uses long chain fatty acids for fuel during periods of 
prolonged fasting so cardiac abnormalities may only be seen once the patient has reached 
a state in which long chain fatty acid oxidation is no longer sufficient (Olpin, 2013). 
There is also research being conducted on the role of the transcription factor PPARα 
(peroxisome proliferator-activated receptor alpha) and cardiac abnormalities seen in those 
with defects of fatty acid metabolism (Bastin, 2014). When inhibitors of fatty acid 
oxidation were given to wild type mice, it was found that the mice could tolerate the 
inhibition (Djouadi et al., 1998).  However, PPARα knockout mice became 
hypoglycemic, suffered cardiac failure, and had lipid accumulation in the heart and the 
liver which resulted in death (Djouadi et al., 1998). This is believed to be due to the 
	15 
upregulation in wild type mice of PPARα leading to the upregulation of fatty acid 
oxidation enzymes in the face of the inhibition (Bastin, 2014). PPARα knockout mice 
could not upregulate fatty acid metabolic enzymes. Further research needs to be done to 
investigate the role of PPARα in the pathophysiology leading to cardiac abnormalities in 
those with MCADD. 
 
Pathophysiology: Production of Toxic Metabolites 
Medium-chain fatty acids that cannot undergo β-oxidation in the mitochondria are 
transported out and are oxidized into carboxylic and dicarboxylic acids that can be toxic 
to the cell (Olpin, 2013). Octanoic Acid, decanoic acid, octanoyl-CoA and cis-4-decenoic 
acid are found to accumulate in those with MCADD with octanoyl-CoA being the most 
toxic. 
Octanoyl-CoA is the most toxic metabolite that accumulates in those with 
MCADD. Octanoyl produces a toxic effect by increasing the acyl-CoA:free CoA ratio 
which leads to the inhibition of gluconeogenesis in the liver (Olpin, 2013). Octanoyl-CoA 
also brings about oxidative damage and depletes glutathione reserves (Olpin, 2013). 
Oxidative damage has been found in a patient with MCADD resulting from the 
accumulation of octanoyl-CoA. Oxidative stress is defined as a “state in which 
production of reactive species cannot be compensated for by the antioxidant defense, 
leading to macromolecule damage” (Derks et al., 2014).  In a study investigating protein 
oxidative damage, decreased plasma sulfhydryl content, indicative of protein oxidative 
	16 
damage, and increased TBARS (thiobarbituric acid reactive species), indicative of lipid 
oxidative damage, were found in patients with MCADD (Derks et al., 2014). Another 
study reported an increased fraction of oxidized phospholipids in those with MCADD 
compared to normal controls (Najdekr et al., 2015). These findings suggest that the 
production of an oxidizing metabolite is responsible for some of the pathophysiology of 
MCADD. 
 
Clinical Presentation 
Stress on the body whether it be an infection, fever, exercise, or fasting can lead to the 
clinical onset of symptoms because of the body’s dependence on fatty acid β-oxidation 
during these states (Grosse et al., 2006). Clinical presentation varies between neonatal 
severe metabolic decompensation to asymptomatic adults who undergo a stressful trigger 
that precipitates the clinical symptoms (Hill et al., 2008).  
The typical initial presentation appears between 3 months and two years of age 
during an episode of fasting or metabolic stress with Reye-like hepatic encephalopathy, 
hypoketotic hypoglycemia and lethargy (Gartner et al., 2015). Reye-like syndrome is 
defined as an acute “encephalopathy accompanied by elevated liver enzymes, serum 
ammonia, and fatty accumulation of the liver” (Wilhelm, 2006). The signs of Reye-like 
hepatic encephalopathy include vomiting, disorientation, loss of consciousness, and 
seizures (Gosalakkal and Kamoji, 2008). Infants are especially susceptible to 
hypoglycemia and low plasma ketones since a large amount of the glucose produced by 
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an infant is utilized in the brain (Olpin, 2013). The liver is also relatively small in infants 
and unable to produce the amount of fuel needed by the brain. Extended periods of 
hypoketotic hypoglycemia in an infant can lead to irreversible brain damage.  Maternal 
milk also has a higher percentage of fat primarily made of medium chain fatty acids 
which will accumulate in the liver of the infant since they cannot be broken down 
(Gartner et al., 2015). Clinical presentation of MCADD is very similar to CPTIA 
(carnitine palmitoyltransferase I A) deficiency. CPTIA deficiency is a defect in the 
carnitine shuttle which transports long-chain fatty acids into the mitochondria for 
oxidation (Bennett, 2010). In patients with CPTIA deficiency, there will be little ketones 
in the urine because the defect impacts most fatty acids; however, in patients with 
MCADD ketones can be found in the urine from the oxidation of long-chain fatty acids 
which are able to enter the mitochondria with a normal CPTI (Bennett, 2010). This can 
be used clinically to distinguish between the two deficiencies.  Initial presentation in 
adulthood is rare for those with MCADD, but there have been cases reported (Lang, 
2009). 
While adult onset is rare, it is important for physicians to keep MCADD in mind 
when an adult presents with Reye-like syndrome and hypoketotic hypoglycemia 
following a significant stressor. The adult presentation is very similar to the infantile 
presentation, but can be considered more life threatening since physicians do not consider 
MCADD in the differential diagnosis and fail to treat the patient correctly. There is a 
50% risk of mortality for those adults presenting with acute symptoms compared with the 
infant mortality risk of 25% (Lang, 2009). Some differences in clinical presentation 
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include cardiac abnormalities and the type of stressor that triggers clinical symptoms. 
Adult onset has been shown to be triggered by drug and alcohol abuse, surgery, and 
pregnancy (Wilhelm, 2006). The presentation of an adult with chronic drug and alcohol 
use can make the diagnosis of MCADD hard, but critical in treatment and survival of the 
patient as described in one case report (Randall et al., 2015). An adult male with a history 
of chronic drug abuse presented with altered mental status, vomiting, abdominal pain and 
thirty pound weight loss over the past three months (Randall et al., 2015). Drug toxicity 
was expected and drug tests were run, but all were negative. Within several hours of 
admission, the patient’s status had deteriorated, he began hallucinating and shortly after 
became unresponsive and died (Randall et al., 2015). Post mortem metabolic testing 
showed he was positive for MCADD. Case reports, such as this one, urge physicians to 
be aware of the adult onset and presentation of MCADD because once diagnosed, 
MCADD can be treated easily. Easy management is the reason why MCADD was added 
to the NBS. 
 
Newborn Screen 
MCADD was added to the NBS in the 1990s. The metabolic decompensation seen in 
those with MCADD can be prevented by avoiding periods of fasting. The hope was that 
by adding it to the newborn screen, the deficiency would be known early on in a patient’s 
life and the mortality and morbidity would be significantly reduced or completely 
eliminated (Blois et al., 2005). Without screening, the mortality rate for MCADD overall 
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is 26% and many patients who survive episodes of severe metabolic decompensation are 
left with permanent neurocognitive disabilities (Grünert et al., 2015). The screen has 
reduced mortality, but has not eliminated it (Nennstiel-Ratzel et al., 2005). The screen 
has revealed a wider range of mutations in the ACADM gene then what was previously 
known to lead to MCADD, the common mutation of c.985A>G representing only 43% in 
one screened cohort (Andresen et al., 2001; Catarzi et al., 2013; Hsu et al., 2008). In the 
United States, MCADD is on the NBS for every state (Hall et al., 2014). Although state 
law dictates what conditions are screened, there is no law saying how to screen for the 
deficiency. It is is up to state laboratories to determine how to screen, and because of this 
there is much debate over which acylcarnitine levels to test, octanoylcarnitine or others, 
as well as the nature of secondary testing (Hall et al., 2014). 
Typically, the NBS for MCADD measures the amount of acylcarnitines in dried 
blood spots by tandem mass spectrometry (Bastin, 2014). Those who are found to be 
positive for octanoylcarnitine are analyzed for mutations and residual enzymatic activity 
(Sturm et al., 2012). Octanoylcarnitine is the primary marker looked at in the NBS, but 
there is debate over how good of a marker it is. Octanoylcarnitine measurements need to 
be evaluated in light of temporal changes in octanoylcarnitine levels (Rhead, 2006). 
Levels are shown to decline between days 1-2 and 6-10 of life and this needs to be taken 
into account when measuring octanoylcarnitine levels in an infant (Rhead, 2006). 
Multiple studies have shown a correlation between the octanoylcarnitine levels and 
sudden infant death in which the higher octanoylcarnitine levels correlated with a higher 
risk of sudden death (Yusupov et al., 2010). This knowledge should be used to inform 
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parents and health care providers of the severe consequences of MCADD in those who 
are positively screened with very high octanoylcarnitine levels above 6 µmol/L (Yusupov 
et al., 2010). It is also important to note that although a correlation has been made with 
octanoylcarnitine levels and sudden death, there has been no correlation between high 
octanoylcarnitine levels and a specific genotype (Sturm et al., 2012).  Secondary 
measures of deceoylcarnitine, octenooylcarnitine, and  octanoylcarnitine:acetylcarnitine 
ratios have also been used in the screen. 
Many studies have shown that the use of not only octanoylcarntine, but also 
deceoylcarnitine, octenoylcarnitine, and octanoylcarntine:acetylcarnitine ratios should be 
used as secondary measures in the NBS (Rhead, 2006). In two studies it was found that 
the octanoylcarnitine:acetylcarnitine ratio was better at diagnosing MCADD and 
distinguishing between patients who were homozygous for the common c.985 A>G 
mutation and heterozygous carriers (Couce et al., 2013; Rhead, 2006). This mutation 
substitutes a lysine for a glutamic acid. The octanoylcarnitine:acetylcarnitine ratio was 
elevated in all those with MCADD and correctly identified two patients that would have 
been missed by just screening for octanoylcarnitine or deceoylcarnitine levels (Couce et 
al., 2013).  Another study showed that octenoylcarnitine levels were a good measurement 
to distinguish very low birth weight baby false positives and true positives (Hall et al., 
2014). The incidence of false positives is highest in very low birth weight babies and the 
use of octenoylcarnitine measurements can help reduce false positives as well as the 
stress on the family and the expense involved in the diagnoses of a metabolic deficiency 
(Hall et al., 2014). Further research and clarification on the best carnitine species to 
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measure may be able to help in diagnosing cases of MCADD that are missed by the 
screen and further lower the mortality. 
 
Genetics 
MCADD is the most common autosomal recessive disorder of the mitochondrial β-
oxidation pathway (Sturm et al., 2012). The deficiency arises from mutations in the 
ACADM gene. The ACADM gene was elucidated in 1992 (Zhang et al., 1992). The gene 
is located on chromosome 1 and is 44 kilobases long, contains 12 exons and 1239 base 
pairs of coding sequence (Gregersen et al., 2001). There have been more than 150 
pathogenic variants identified including 114 missense mutations, 19 splicing mutations, 
13 small deletions, six small insertions and three large deletions (Matern and Rinaldo, 
1993; Smith et al., 2010). There have been efforts to come up with genotype-phenotype 
relationships in order to classify the genotype based on biomarkers like plasma 
acylcarnitine levels (Koster et al., 2014; Smith et al., 2010). These studies attempted to 
characterize the many variant MCAD enzymes that results from different combinations 
of mutations. These genotype-phenotype relationships are still being worked out, but it 
has been found that residual enzyme activity as a result of a particular mutation is the 
greatest indicator of phenotype (Touw et al., 2013). An ethnicity factor may also need to 
be considered when genotyping.  
Ethnicity seems to play a role in the type of mutations found in those with 
MCADD. The most common variant in the European descent, Caucasian population is 
	22 
the c.985A>G mutation, which will be characterized in the first part of this thesis. This 
mutation is not typically found in Asian populations (Tajima et al., 2016). Additionally, 
there were no reported cases of MCADD in the Asian population until 2000 and a NBS 
was not started in Japan until 2014 (Hara et al., 2016). The first Korean patient was 
diagnosed in 2005 and was found to have a 4 base pair deletion that was also identified in 
Japanese infants diagnosed with MCADD (Ensenauer et al., 2005). This 4 base pair 
deletion is being studied and may be a common Asian variant. However, further genetic 
analysis in those of Asian descent with MCADD must be done in order to determine if a 
common Asian variant exists. 
 
Specific Aims 
 
The specific aims of this thesis include: 
1. Comprehensive review of the literature to characterize the most common variant 
of the ACADM gene leading to MCADD. 
2. Review of the current therapeutics for MCADD. 
3.  Investigation of future pharmacological therapeutics for MCADD by studying 
pharmacological therapeutics for other inborn errors of metabolism. 
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CHARACTERIZATION OF THE MOST COMMON VARIANT OF MEDIUM-
CHAIN ACYL-COA DEHYDROGENASE RESULTING IN MCADD 	
The c.985A>G missense mutation in the ACADM gene represents the most common 
variant of the medium-chain acyl-CoA dehydrogenase (MCAD) enzyme leading to 
MCADD. The variant accounts for 90% of defective alleles found in patients who are 
diagnosed after a severe metabolic decompensation and it is considered the most 
clinically severe variant (Maier et al., 2009). The A985G missense mutation results in a 
glutamic acid for lysine substitution in the precursor protein at position 329 (K329E) and 
position 304 in the mature protein (K304E) (Grosse et al., 2006). This variant has been 
associated with the highest plasma octanoylcarnitine levels in patients who are 
homozygous for the mutation (Couce et al., 2013). However, high octanoylcarnitine 
levels have been found in patients with other mutations and so there cannot be a direct 
phenotypic correlation with the most common variant genotype as of yet. There have 
been many attempts to characterize the enzymatic product of this most common variant. 
The following part of this thesis will summarize literature which reports on the structure 
of MCAD and analyzes the protein misfolding, aggregation, catalytic pocket formation 
and activity, thermostability, and motion patterns of the K329E variant. 
 
Structure of wild type human MCAD 
MCAD belongs to the acyl-CoA dehydrogenase family of flavoproteins (Maier et al., 
2009). The family consists of nine members, five of which are involved in fatty acid 
oxidation and the remaining four are involved in amino acid oxidation (Kim and Miura, 
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2004). The five members involved in fatty acid oxidation are short-chain acyl-CoA 
dehydrogenase, medium-chain acyl-CoA dehydrogenase, long-chain acyl-CoA 
dehydrogenase, very long-chain acyl-CoA dehydrogenase 1, and very long-chain acyl-
CoA dehydrogenase 2 (Kim and Miura, 2004). All members have varying affinities for 
different chain lengths of fatty acids.  MCAD has affinity for C6-C12 chain length fatty 
acids and is the most understood and studied enzyme in the acyl-CoA dehydrogenase 
family (Bonito et al., 2016).  
MCADD is a homotetrameric enzyme and each monomer is composed of three 
structural domains: the N-terminal α domain, the central β domain, and the C-terminal α 
domain (Maier et al., 2009). Each domain is relatively the same size (Kim and Miura, 
2004). The N- and C-terminal comprise the core of the protein and the central β domain 
makes up the surface of the enzyme (Maier et al., 2009). The catalytic site lies within the 
interface of the β domain and the C-terminal α domain and holds the binding sites for the 
FAD cofactor and acyl-CoA substrates (Maier et al., 2009). Each monomer binds one 
FAD and one acyl-CoA substrate as can be seen in Figure 5 (Bonito et al., 2016). The 
tetrameric molecule is a dimer of dimers with a diameter of 90 Angstroms (Kim and 
Miura, 2004). Two monomers come together in a dimer through an interaction that 
involves the FAD binding domain and two dimers come together through a helix-helix 
interaction to form the tetramer (Figure 5B) (Kim and Miura, 2004). The K329E lies at 
the dimer-dimer interface and is located on the long alpha helix H (Nasser et al., 2004). 
The mutation has not been shown to impact the secondary structure of the protein, but it 
has been shown to significantly affect the quaternary structure (Yokota et al., 1992). 
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Figure 5: Ribbon Diagrams of MCAD Structure 
(A) Fold of a monomer of the MCAD enzyme. Composed of three structure units, the N- 
terminal α domain, the central β domain and the C-terminal α domain. The solid balls 
represent the bound FAD and acyl-CoA substrates. (B) Folded tetramer of the MCAD 
with FAD and acyl-CoA substrates shown in solid balls in each monomer. Adapted from 
(Kim and Miura, 2004) 
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Proteolytic stability 
The K329E variant was studied to see if it is more susceptible to cleavage by proteases 
compared to the wild type MCAD enzyme. It was found that the K329E variant had a 
decay constant of proteolysis that was significantly higher than the wild type (Bonito et 
al., 2016). Also, the variant was found to have significantly less (56.1%) full length 
protein around after 30 min of proteolysis with trypsin compared to wild type (74.8%) 
(Bonito et al., 2016; Maier et al., 2009). These findings show that the K329E variant is 
more susceptible to proteolytic degradation than wild type. This suggests that the 
mutation alters the overall conformation of the MCAD enzyme. 
 
Protein Misfolding and Aggregation 
In studies of protein misfolding of the K329E variant, it was found that there was an 
increase in the amount of monomeric forms of the protein and a decrease in the 
tetrameric form (Bonito et al., 2016; Yokota et al., 1992). A reduction in the tetrameric 
form is believed to be due to the substitution of a positive amino acid for a negative one 
in position 329 in the precursor and 304 in the mature protein which creates hindrance 
and impacts monomer and thus tetramer formation (Bross et al., 1995). Figure 6 shows 
the location of the positive lysine (K) residue at position 304 in the mature wild type 
protein and its proximity to the negatively charged aspartic acid (D). Tetrameric form of 
a lab generated K304E mutant was rescued with the co-overexpression of the chaperones, 
GroES and GroEL, another indicator that protein misfolding plays a role in the 
pathogenesis of MCADD (Maier et al., 2009). 
	27 
 
 
 
Figure 6: Close-up of position 304 in MCAD.  
The lysine residue at position 304 (K304) is located in close proximity to two aspartic 
acid residues (D346 and D300). The substitution of a negatively charged glutamic acid 
(E) at position 304 in the K304E variant causes hindrance and results in protein 
misfolding. Circled letters indicate alpha helices (K, H, I). Q, glutamine; R, arginine. 
Adapted from (Nasser et al., 2004) 
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Catalytic Activity and Catalytic Pockets 
In studies of protein aggregation, it was found that there was a decrease in the amount of 
soluble protein consistent with an increased opportunity for aggregation (Maier et al., 
2009). High molecular weight aggregates were also found with the K329E variant 
(Bonito et al., 2016; Maier et al., 2009).	Unable to form tetramers, the monomers 
aggregate and are non-functional. Together, results from protein misfolding and 
aggregation studies suggest that the K329E variant is pathogenic because it causes the 
misfolding of the MCAD protein and a reduction in tetramer formation. To see how the 
misfolding impacts the catalytic activity, studies were done to assesses the catalytic 
pockets of the K329E variant compared to wild type. 
The catalytic activity and the catalytic pockets of the K329E variant were both 
found to be different from the wild type human MCAD. The K329E variant was shown to 
have decreased enzyme activity with 46% residual activity (Bonito et al., 2016). A lower 
Vmax  and a higher Km were also reported for the variant compared to wild type, 
suggesting a decrease in the catalytic efficiency of the variant (Kieweg et al., 1997). Km 
represents the concentration of substrate needed for 50% of the enzyme to be occupied 
and a higher Km correlates with a lower affinity of the enzyme for the substrate. Vmax 
represents the maximum velocity of the reaction and a lower Vmax means a slower rate of 
reaction. The graphs in Figure 7 show the ratio of Vmax/ Km, a measurement of the 
catalytic efficiency, for both the variant and wild type MCAD. It can be seen that the 
K329E variant has reduced catalytic efficiency, especially for octanoylcarnitine (Kieweg 
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et al., 1997). In view of the difference in the catalytic activity of the variant, catalytic 
pocket formation was then analyzed. 
 
 
 
 
Figure 7: Substrate Chain Length and Catalytic Efficiency of K329E ([Glu304] 
MCADH) variant and wild type MCAD (MCADH). Vmax/Km is a measurement of the 
catalytic efficiency. The variant is shown to have lower catalytic efficiency at most 
substrate chain lengths compared to the wild type. Adapted from (Kieweg et al., 1997). 
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The formation of the catalytic pocket is critical for the enzyme to carry out the 
dehydrogenation reaction. It was previously thought that the binding of the FAD cofactor 
is essential to the structure of MCAD and the formation of the catalytic pocket (Kim et 
al., 1993). Studies of wild type human MCAD catalytic pockets proved this, as they were 
found to increase in volume in the presence of both the FAD cofactor and acyl-CoA 
substrates (Bonito et al., 2016). However, the size of the catalytic pockets of the K329E 
variant remained the same either in the presence or the absence of the FAD and increased 
significantly only in the presence of the acyl-CoA substrate (Bonito et al., 2016). A lower 
binding affinity was found for FAD and acyl-CoA substrate in the variant enzyme and the 
lower affinity was localized to only two of the four monomers of the tetramer (Bonito et 
al., 2016; Jank et al., 2014). Finding that only two monomers of the variant were showing 
abnormal binding affinities, studies looked closer at the catalytic sites of each monomer. 
 
All four variant monomers of the K329E variant were shown to have differences 
in their catalytic sites compared both to each other and to the wild type MCADD enzyme. 
In one of the four monomers of the variant, the structure of the binding pocket and the 
relative position of the FAD cofactor and acyl-CoA substrate remained about the same as 
wild type (Bonito et al., 2016). The substrate normally binds between the carboxylate 
group of the Glu376 residue and the flavin ring of the FAD cofactor as seen in Figure 8. 
This positioning and structure was conserved in one monomer (Stankovich et al., 1999). 
In another monomer of the variant tetramer, the structure of the catalytic pocket was 
unaffected, but there was a change in the position of the substrate and FAD binding site 
(Bonito et al., 2016). Although the positioning is changed, this monomer likely undergoes 
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the dehydrogenation reaction and functions normally (Jank et al., 2014). The last two 
monomers of the tetramer had severe structural changes that resulted in a non-functional 
catalytic unit. In these monomers, a large portion of the substrate was exposed to the 
polar water environment and there was a large distance between the FAD cofactor, acyl-
CoA substrate, and catalytic residues on the enzyme (Bonito et al., 2016). These 
structural changes made it so that the dehydrogenation reaction could not occur. 
Importantly, these findings suggested that only one dimer of the K329E MCAD enzyme 
is directly affected by the mutation and this may be why the variant retains 46% residual 
activity (Bonito et al., 2016; Jank et al., 2014). Although only one dimer seems to be 
directly affected by the mutation, the overall conformation of the protein is defective as 
shown in the proteolytic studies (Bross et al., 1995). Interestingly, studies on the 
thermostability and motion patterns of the K329E variant also showed that only one 
dimer is directly affected by the mutation. 
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Figure 8: Sketch of Substrate Binding. The acyl-CoA substrate binds between the FAD 
cofactor and the carboxylate group of the Glu376 residue in the MCAD enzyme. Correct 
orientation of these residues is needed for the dehydrogenation reaction to proceed. 
Adapted from (Stankovich et al., 1999). 
 
 
Thermostability 
The thermostability of the MCAD enzyme was studied because of the precipitation of 
clinical symptoms and metabolic decompensation seen in those with MCADD during 
febrile illnesses (Koster et al., 2014). Thermal denaturation profiles were computed for 
both the wild type MCAD and the K329E variant. The profiles showed that there were 
two major transitions or denaturation patterns within both the wild type enzyme and the 
K329E variant resulting in two melting temperatures (Tm) (Jank et al., 2014) (Figure 9). 
One of the melting temperatures was found to be 3.5 °C lower in the variant compared to 
wild type, while the other Tm was the same as the wild type (Nasser et al., 2004). These 
findings suggest that the mutation effects one structural domain, leaving the other 
unaffected. Particularly, it is hypothesized that the first melting temperature corresponds  
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Figure 9: Accelerated Heat Unfolding in the K329E variant. (Left) The red lines on 
the graph show the two temperature transitions observed in both the wild type and the 
variant. αDN indicates the N-terminal α domain. (Right) The K329E variant is shown in 
red and wild type in black. αDC indicates the C-terminal α domain where the mutation is 
located. Adapted from (Jank et al., 2014). 
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to the more unstable β domain of the protein while the second melting temperature 
corresponds to the α domains which are more stable (Jank et al., 2014). This supports the 
results found in studying the catalytic pockets of the variant which found two monomers, 
one dimer, directly affected by the mutation (Bonito et al., 2016). Protein aggregation at 
high temperatures was also studied. It was found that the K329E variant aggregated faster 
in a temperature that mimicked a fever compared to wild type (Bonito et al., 2016). The 
K329E variant is more susceptible to denaturation in the face of high temperatures. 
 
Motion Patterns 
The movement of the enzyme in the presence of the FAD cofactor and acyl-CoA 
substrate was studied in both the wild type and K329 variant to determine if the mutation 
affected the whole tetramer. In one study, the monomers of the wild type MCAD showed 
small movements in the presence of the FAD cofactor and acyl-CoA substrate, but these 
movements did not affect the stability of the whole tetramer (Bonito et al., 2016). 
Although the protein core was the most stable, small fluctuations were seen around the β 
domain which holds the catalytic site (Bonito et al., 2016). In the K329E variant, distinct 
differences in movement were found between the two dimers and this is believed to lead 
to the overall instability of the tetramer (Bonito et al., 2016). Each monomer of the 
variant was also found to have increased movement fluctuations compared to the wild 
type (Bonito et al., 2016). These data support and prove further that the mutation in the 
K329E variant produces its largest effect in the β domain of the enzyme, but has an effect 
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on the overall structure of the protein making it more susceptible to proteolysis and heat 
denaturation. 
Now that the most common variant of the MCAD enzyme implicated in MCADD 
has been characterized, the next part of this thesis will focus on therapeutics starting with 
current therapies and ending with future therapeutics. 
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CURRENT THERAPEUTICS 	
Acute Treatment 
When a patient with MCADD presents with clinical symptoms, it is important to 
immediately correct the hypoglycemia. Delay of treatment can result in permanent brain 
damage and in the worst cases, sudden death (Saudubray et al., 1999). Intravenous 
infusion of 10% glucose should be administered if the patient is unconscious or not 
responding (Saudubray et al., 1999). If the patient is awake, glucose tablets or sweetened 
non-diet drinks can be given (Matern and Rinaldo, 1993). A blood sugar level should be 
maintained at or above 5 mmol/L in such individuals (Saudubray et al., 1999). It is 
important for those with MCADD to carry an emergency notecard or letter explaining the 
acute treatment and manifestation of MCADD to healthcare providers that may be 
unaware of the condition, because correct early treatment can prevent severe 
decompensation, brain damage and death (Matern and Rinaldo, 1993). 
 
Avoidance of Fasting 
The major component of daily and long term care of those with MCADD is a strict 
avoidance of fasting. Fasting is to be avoided so that the patient’s body does not enter 
into a state where fatty acids or ketones are relied upon as fuel. It is very important that 
parents and healthcare providers are aware of the severe dangers of fasting (Boyer et al., 
2015). Because all of the genotypes have not been characterized and linked to a risk of 
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metabolic decompensation, it is important that avoidance of fasting and emergency 
regimens are at hand for all patients with MCADD, regardless of genotype (Touw et al., 
2013). Trained metabolic dietitians are also important members of the multidisciplinary 
care team of a patient with MCADD, although there are no special dietary restrictions 
(Boyer et al., 2015). 
No dietary restrictions are placed on those with MCADD. There has been debate 
about the benefits of a low fat diet and although this is recommended in patients with 
other defects of fatty acid oxidation, it is not recommended for those with MCADD 
(Boyer et al., 2015). However, medium chain triglycerides should be avoided if a patient 
is in a state of metabolic decompensation. Infant formulas or breast milk that is enhanced 
with medium chain triglycerides should also be avoided (Boyer et al., 2015; Rector and 
Ibdah, 2010). In adults, alcohol consumption especially binge drinking has been shown to 
lead to metabolic decompensation and should be avoided (Lang, 2009).  A balanced diet 
with appropriate caloric and nutritional intact for the age and size of the patient for 
normal body growth and development is recommended (Boyer et al., 2015). Patients 
should have emergency concentrated glucose for hypoglycemic emergencies, and if 
fasting is required for a medical procedure, IV glucose should be administered (Boyer et 
al., 2015; Derks et al., 2007). A strict avoidance of fast is part of the daily care of those 
with MCADD and many studies have worked on determining the specific amount of 
fasting that can be tolerated. 
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Compared to other inborn errors of metabolism, MCADD patients have been 
shown to tolerate normal periods without food; however, patients still need to be 
carefully monitored (Walter, 2003). One study looked at fasting studies of 35 patients 
with MCADD (Derks et al., 2007). They defined the safe fasting blood glucose level to 
be greater than 2.6 mmol/L, but found that in 6 of the patients acute symptoms were 
manifested before hypoglycemia, blood glucose levels below 2.6 mmol/L, could be 
measured (Derks et al., 2007). This re-affirmed the warning that those with MCADD 
should avoid fasting and be aware of clinical symptoms so that they can seek help before 
progressing into a metabolic decompensation (Walter, 2009). There has been a movement 
to try to standardize or organize data regarding the recommended fasting times in those 
with MCADD. 
An organization of international Genetic Metabolic Dieticians has reported on 
fasting protocols depending on age. They report that in infancy between birth and 4 
months of age, those with MCADD should be fed at the same frequency as those without 
MCADD, about every 4 hours (Derks et al., 2007). Between 5 and 12 months, an hour of 
fasting can be added for each month increase in age, and blood glucose levels can be 
measured in the morning in order to see how the infant tolerated the overnight fast and 
individualize fasting hours (Derks et al., 2007). In adulthood, those with MCADD should 
avoid skipping a meal or taking up weight loss diets which recommend fasting (Grosse et 
al., 2006). There are also national recommendations for the maximum hours of fasting 
and an example of those used in the U.K., Australia, and Germany are presented in Table 
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1. Because of the varying fasting times recommended in each nation, patients should 
work with their physician to find a maximum fasting time that works for them. 
Table 1: Recommended fasting times from the British Inherited Metabolic 
Disease Dietician Group. Adapted from (Walter, 2009). 
 
Age (months) Maximum fasting 
time for children 
with MCADD in 
Germany (hours) 
Maximum fasting 
time for children 
with MCADD in 
Australia (hours) 
Maximum fasting 
time for children 
with MCADD in 
the UK (hours) 
1 6 4 6 
2 6 4 6 
3 6 4 6 
4 6 4 8 
5 6 6 8 
6 6 6 8 
7 8 8-10 8 
8 8 8-10 10 
9 8 8-10 10 
10 8 8-10 10 
11 8 8-10 10 
1 year old 8 12 12 
2 years old 8 12 12 
3 years old 8 12 12 
Greater than 4 years 
old 
10 12 12 
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L-Carnitine Supplementation 
L-carnitine supplementation was first used in those with MCADD because of the 
secondary deficiency in carnitine found in some patients (Spiekerkoetter et al., 2010). 
Carnitine was first found in muscle tissue about a hundred years ago and almost all of the 
body’s carnitine is stored in skeletal muscle tissue (Stephens et al., 2007). In skeletal 
muscle, its most well studied role is to help in the translocation of fatty acids into the 
mitochondria for β-oxidation (Stephens et al., 2007). In terms of treatment for MCADD, 
it is suggested to reduce the severity of metabolic decompensation, perhaps by allowing 
entry of more fatty acids into the mitochondria for subsequent oxidation, but there have 
been no studies validating this claim (Spiekerkoetter et al., 2010). Supplementation with 
carnitine may also work by preventing a deficiency in free carnitine which could come 
about due to the high levels of acylcarnitines seen in those with MCADD. Carnitine 
supplementation is mostly used in carnitine transporter deficiency and very-long-chain 
acyl-CoA dehydrogenase deficiency. It has been shown to be efficacious in the long term 
treatment of those two conditions, but there is no high quality evidence for its efficacy in 
those with MCADD (Spiekerkoetter et al., 2010; Walter, 2003). There is considerable 
variability in the preference of physicians to use L-carnitine supplementation for long-
term care of those with MCADD (Potter et al., 2012). This is probably due to the lack of 
research done testing L-carnitine supplementation for long-term MCADD treatment and 
the contrasting findings found on L-carnitine supplementation and its effect on exercise 
in those with MCADD.  
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There have been a significant number of studies done studying L-carnitine 
supplementation and its effect on exercise in those with MCADD, but the results have 
been contradictory. In 2005, a study was done which tested four patients with MCADD 
during incremental ramp exercise before and after 4 weeks of L-carnitine 
supplementation (Lee et al., 2005). All four patients were asymptomatic at the time of the 
study and acted as their own controls. L-carnitine was given at a dose of 100 mg/kg per 
day. Plasma and urinary acylcarnitines were measured before and after exercise. 
Measurements of exercise performance were also taken. Plasma and urinary 
acylcarnitines were found to increase during exercise without supplementation and 
increased further with L-carnitine supplementation (Lee et al., 2005). Those with L-
carnitine supplementation were shown to have improvement in measures of exercise 
tolerance (Lee et al., 2005). Peak oxygen uptake was shown to have an 18-32% 
improvement, oxygen pulse had a 10-32% improvement, VO2 at a heart rate of 170 
beats/min was found to have a 15-23% improvement, and VO2 at the anaerobic threshold 
was found to have a 27-42% improvement (Lee et al., 2005). Anaerobic threshold is the 
point at which skeletal muscle greatly increases its anaerobic metabolism (Lee et al., 
2005). This study showed that L-carnitine supplementation increased the clearance of 
acylcarnitines during exercise in those with MCADD because of the increased plasma 
and urinary levels of acylcarnitines. An increased clearance of acylcarnitines is important 
because of the accumulation of toxic acylcarnitine intermediates found in those with 
MCADD (Huidekoper et al., 2006). However, a study in 2006 found no benefit to L-
carnitine supplementation during exercise. 
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Another study tested five patients with MCADD versus three controls during 
prolonged moderate-to-intense exercise with and without L-carnitine supplementation 
(Huidekoper et al., 2006). Patients were studied during 2 hours of moderate-to-intense 
exercise after a 12 hour fast before and after L-carnitine supplementation of 50 mg/kg per 
day (Huidekoper et al., 2006). Blood and urinary acylcarnitine levels were measured 
before and after exercise. As was found in the 2005 study, acylcarnitine levels, 
particularly octanoylcarnitine levels, were found to rise during exercise in patients 
without supplementation. This shows that fatty acid oxidation increases during exercise 
in those with MCADD. Patients who received L-carnitine supplementation were found to 
have even higher plasma and urinary acylcarnitine levels like what was found in the 2005 
study supporting the increased clearance of acylcarnitines in those with supplementation 
(Huidekoper et al., 2006). However, no benefit was observed in those who were 
supplemented. Perhaps, L-carnitine is beneficial if an MCAD deficient patient 
participates in short periods of intense exercise as tested in the 2005 study. However, 
during prolonged periods of intense exercise, there is no benefit, though the authors of the 
2006 study said that it cannot be ruled out (Huidekoper et al., 2006). 
The contrasting results of studies done on L-carnitine supplementation during 
exercise in those with MCADD make it difficult for physicians to decide to use it 
clinically. In 2013, another study was done which found that L-carnitine supplementation 
did not increase fatty acid oxidation in those with MCADD (Madsen et al., 2013). 
Patients who underwent L-carnitine supplementation also had side effects including 
nausea, diarrhea, abdominal pain, and a “heavy fish-like odor” (Madsen et al., 2013).  In 
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the future, there needs to be standardized studies on the use of L-carnitine 
supplementation in exercise in those with MCADD. Studies also need to be designed that 
would show the long term efficacy of L-carnitine supplementation in those with 
MCADD. Until studies like those are completed, there will not be a consensus on L-
carnitine supplementation for the treatment of MCADD. Currently, there are no approved 
pharmacological interventions for the treatment of MCADD. The final part of this thesis 
will explore future therapies, including pharmacological therapies that may be used for 
the long-term treatment of MCADD. 
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FUTURE THERAPEUTICS 	
Gene Therapy 
Promising in vitro studies of MCADD fibroblasts were done in 2005, but there has been 
no attempt since to try gene therapy in vivo (Matern and Rinaldo, 1993). A recombinant 
first-generation adenovirus vector expressing the human MCAD protein under the 
cytomegalovirus promoter was prepared and human fibroblasts deficient in MCAD were 
infected with the adenovirus (Schowalter et al., 2005). The co-localization of the stained 
MCAD protein and the mitochondrial dye proved that the protein made it to the 
mitochondria in MCAD deficient human fibroblasts after being infected with the 
adenovirus (Schowalter et al., 2005). MCAD deficient fibroblasts were also found to 
have lower acylcarnitine levels, particularly octanoylcarnitine, after being infected with 
the MCAD adenovirus (Schowalter et al., 2005). This showed that the adenovirus, by 
producing functional MCAD, removed the metabolic block and reduced the levels of 
toxic metabolites that accumulate in MCADD. These studies showed that the adenovirus 
worked in vitro; however, there are concerns when moving to an in vivo model.  
Adenoviruses are known to elicit a strong immune response in vivo (Schowalter et 
al., 2005). The hope is that because most patients with MCADD have at least one allele 
of a common variant, K329E, which produces a non-functional protein, there will be a 
decreased risk of MCAD neutralizing antibody formation (Vockley and Whiteman, 
2002). Hepatocyte specific promoters such as that of albumin are suggested for use in in 
vivo models to help with immunogenicity (Pastore et al., 1999). There have been no 
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studies testing an adenovirus in vivo for MCAD, though in vitro studies are promising. 
Future in vivo studies need to be done to see if gene therapy can be used as a treatment 
for MCADD 
 
Bezafibrate  
Bezafibrate (BEZ) is an approved hypolipidemic drug for cardiovascular disease 
(Yamaguchi et al., 2012). BEZ is an agonist for the peroxisome proliferating activator 
receptor alpha (PPARα) and it acts by inducing multiple enzymes of the fatty acid 
oxidation pathway (Aoyama et al., 1998; Yamaguchi et al., 2012). PPARα is part of the 
nuclear/steroid receptor family that binds and mediates the effects of peroxisome 
proliferators (Aoyama et al., 1998). Peroxisomes are the only other organelles in the 
body, besides the mitochondria, where fatty acid β-oxidation can take place (Aoyama et 
al., 1998). PPARα null mice were shown to have a significantly decreased level of fatty 
acid oxidation enzymes including very-long-chain acyl-CoA dehydrogenase, long-chain 
acyl-CoA dehydrogenase, and short-chain acyl-CoA dehydrogenase while medium-chain 
acyl-CoA dehydrogenase remained the same (Aoyama et al., 1998). However, the 
peroxisome proliferator response element was found on the gene that codes for MCAD 
and PPARα was shown to trans-activate the MCAD gene (Aoyama et al., 1998; Gulick et 
al., 1994). BEZ is a PPARα agonist, but it is not known whether it functions in MCADD 
models by inducing the mutant defective enzyme or by inducing other enzymes of fatty 
acid oxidation. 
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One study used an in vitro probe acylcarnitine assay to evaluate the effects of 
BEZ on various fatty acid oxidation disorders (Yamaguchi et al., 2012). MCAD deficient 
fibroblasts were shown to have a characteristic octanoylcarnitine peak on analysis before 
BEZ (Yamaguchi et al., 2012). After BEZ, octanoylcarnitine levels in MCAD deficient 
fibroblasts reduced to near normal levels (Yamaguchi et al., 2012) (Figure 10). It was 
still unclear whether BEZ works by inducing MCAD or other fatty acid oxidation 
enzymes. Another study showed that BEZ increased the amount of mRNA of very-long-
chain acyl-CoA dehydrogenase in very-long-chain dehydrogenase deficient patients as 
well as MCAD mRNA in MCADD patients (Djouadi et al., 2005). It is still unclear how 
it functions to reduce octanoylcarnitine levels in those with MCADD, and future studies 
specifically exploring BEZ in MCADD patients are needed to determine if it can be used 
as a treatment. It is currently being investigated in clinical trials as a therapy for very-
long-chain acyl-CoA dehydrogenase deficiency and patients have had some side effects 
including hypolipidemia and rhabdomyolysis (Bonnefont et al., 2009, 2010). 
 
 
 
 
 
	47 
 
 
 
 
Figure 10: Acylcarnitine Levels in Control Fibroblasts and MCAD Deficient 
Fibroblasts. Acylcarnitine levels in control fibroblasts (A) and MCAD deficient 
fibroblasts (H) before and after introduction of BEZ. In MCAD deficient fibroblasts, 
characteristic octanoylcarnitine peaks were reduced to near normal levels after BEZ was 
introduced. Unit of vertical line is nmol/mg protein of acylcarnitine. Horizontal line 
represents acylcarnitines. Adapted from (Yamaguchi et al., 2012) 
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Pharmacological Chaperones 
The pathogenesis of MCADD results from the production of a non-functional protein. As 
shown in studies of the most common variant of the MCAD protein, K329E, the protein 
is non-functional due to protein misfolding and it is highly susceptible to breakdown by 
trypsin and denaturation from heat (Bonito et al., 2016; Jank et al., 2014).  The 
development of pharmacological chaperones that would rescue the function of the 
MCAD protein could be a future strategy for the treatment of MCADD (Jank et al., 
2014). Pharmacological chaperones that act in this way are approved for phenylketonuria 
and will now be discussed. 
Pharmacological chaperones are “natural ligands of the target protein that can 
rescue misfolded conformers of these proteins by stimulating their renaturation or 
scaffolding of the final folded structure” (Underhaug et al., 2012). They were first 
worked out using the energy dependent transporter, P-glycoprotein or multi-drug 
resistance gene-1 product (Loo and Clarke, 1995). Use of natural substrates and inhibitors 
of the P-glycoprotein lead to the appearance of the functional protein in the membrane 
(Loo and Clarke, 1995). It was hypothesized that the substrates bound to an early form of 
the P-glycoprotein, stabilized an intermediate, and allowed the protein to fold correctly, 
and the term “pharmacological chaperones” was later used to imply this mechanism of 
protein renaturation (Bernier et al., 2004). Pharmacological chaperones represent a more 
selective type of chaperone that should result in less toxic effects when used in patients 
compared to chemical chaperones (Morello et al., 2000). They have been studied in many 
diseases whose pathology results from misfolded protein and a pharmacological 
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chaperone is currently approved for the treatment of phenylketonuria (Loo and Clarke, 
2007). 
Similar to MCADD, phenylketonuria is an autosomal recessive inborn error of 
metabolism that results from the misfolding of a mutant phenylalanine hydroxylase 
enzyme (Underhaug et al., 2012). Phenylalanine hydroxylase catalyzes the first step in 
the amino acid metabolism pathway of phenylalanine, an essential amino acid 
(Underhaug et al., 2012). The deficiency is characterized by elevated levels of 
phenylpyruvate and phenylalanine in the blood and tissues due to inefficient normal 
metabolism. The natural cofactor, tetrahydrobiopterin, is a natural chaperone and can be 
considered pharmacological when given in therapeutic supplementation (Underhaug et 
al., 2012). Sapopterin dihydrochloride is a pharmaceutical preparation of 
tetrahydrobiopterin that has been approved as a pharmacological chaperone in 
phenylketonuria (Trefz et al., 2009). In clinical trials, sapopterin dihydrochloride was 
proved to be effective in increasing phenylalanine tolerance in those with 
phenylketonuria (Trefz et al., 2009). In the sapropterin group, 12 of 33 subjects tolerated 
a 10 mg/kg/d of phenylalanine supplements and 21 subjects were able to tolerate even 
higher doses (Trefz et al., 2009). No subjects in the placebo group were able to tolerate 
greater than 10 mg/kg/d of phenylalanine and 7 out of the 12 were not able to tolerate any 
phenylalanine supplement at all (Trefz et al., 2009). Sapopterin dihydrochloride is now 
approved and sold as Kuvan ® (Muntau et al., 2017). 
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CONCLUSIONS AND FUTURE DIRECTIONS 	
Medium-chain acyl-CoA dehydrogenase deficiency is the most common inborn error of 
metabolism. The biochemical and pathophysiological basis of the deficiency have been 
well studied and the knowledge that early intervention can prevent severe side effects and 
reduce the mortality of MCADD led it to be added to the NBS. Introduction in the NBS 
led to more knowledge of the genetics of MCADD and the characterization of not only 
the most common variant leading to MCADD, but also the characterization of those 
genotypes linked to a milder phenotype. However, there have not been extensive studies 
done on the treatment of MCADD. 
Because MCADD is well controlled by an avoidance of fasting, there has been 
little research in the realm of pharmacological therapies for MCADD. In the future, 
studies based on those done for phenylketonuria may open up the door for 
pharmacological chaperones in the treatment of MCADD. Like tetrahydrobiopterin and 
phenylalanine hydroxylase, looking at the FAD cofactor of MCAD may be a starting 
point and it should be studied to determine if it is a natural chaperone that could rescue 
the correct folding and conformation of the protein. Studies for pharmacological 
interventions may seem irrelevant or not needed, but avoidance of fasting does not 
prevent metabolic decompensation in all patients. Those with MCADD are still at a high 
risk for metabolic decompensation and death even with an avoidance of fast. 
Pharmacological chaperones or other pharmacological therapeutics, such as gene therapy, 
could have the potential to correct the defective enzyme and eliminate the morbidity. 
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